Showing results (101-110 of 111) with videos related to
Sort By:
Pageof 12
International Journal of Oncology|March 14, 2013
Increased in vivo angiogenic effect of glioma stromal mesenchymal stem-like cells on glioma cancer stem cells from patients with glioblastomaByung Ho Kong, Hyun-Do Shin, Se-Hoon Kim, et al.Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|November 13, 2012
Isolation of glioma cancer stem cells in relation to histological grades in glioma specimensByung Ho Kong, Na-Ri Park, Jin-Kyoung Shim, et al.Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|January 1, 2013
Existence of glioma stroma mesenchymal stemlike cells in Korean glioma specimensYoung Goo Kim, Soyoun Jeon, Ga-Yeong Sin, et al.Cancer Research and Treatment|November 2, 2019
Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)Kihwan Hwang, Tae Min Kim, Chul-Kee Park, et al.Neuro-Oncology|March 18, 2020
Crosstalk between GBM cells and mesenchymal stemlike cells promotes the invasiveness of GBM through the C5a/p38/ZEB1 axisEun-Jung Lim, Seungmo Kim, Yoonjee Oh, et al.Cancer Research and Treatment|July 8, 2021
Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)Grace S Ahn, Kihwan Hwang, Tae Min Kim, et al.Journal of Neuro-Oncology|August 12, 2018
Impact of adjuvant treatments on survival in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup studyTaeryool Koo, Do Hoon Lim, Ho Jun Seol, et al.Journal of Neuro-Oncology|March 25, 2018
Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup studyTaeryool Koo, Do Hoon Lim, Ho Jun Seol, et al.Journal of Korean Neurosurgical Society|February 15, 2014
Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytomaHo-Shin Gwak, Gi Taek Yee, Chul-Kee Park, et al.The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.Pageof 12